MAPT and Alzheimer disease: Disease modifying therapies (DMT) for AD have been explored in the past several decades, mainly targeting Aβ, tau, neuroinflammation, enzymes that control neurotransmitter levels, and neurotransmitter receptors to alleviate clinical symptoms.